In Q3 2023, OrbiMed Advisors held 85 positions worth $3.8B. They initiated 11 new positions and exited 16. Their largest holding was SVA ($340.0M). Portfolio value shrank -9.6% versus the prior quarter.
Frequently asked questions
What stocks did OrbiMed Advisors own in Q3 2023?
OrbiMed Advisors held 85 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include SVA, BSX, HUM, ISRG, BIIB. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was OrbiMed Advisors's portfolio worth in Q3 2023?
OrbiMed Advisors's tracked biotech portfolio was worth $3.8B across 85 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
What did OrbiMed Advisors buy in Q3 2023?
OrbiMed Advisors initiated 11 new positions in Q3 2023, including MRK, ABBV, ICLR, APGE, NMRA and 6 more. They also increased 9 existing positions.
What did OrbiMed Advisors sell in Q3 2023?
OrbiMed Advisors fully exited 16 positions in Q3 2023, including NKTR, MREO, NTLA, AMLX, SYRE and 11 more. They also trimmed 19 existing positions.
Is OrbiMed Advisors a biotech fund?
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Want AI analysis, insider signals, and catalyst overlays for OrbiMed Advisors?
View latest OrbiMed Advisors portfolio →